Genentech Ends Enbrel Manufacturing Agreement; Amgen Says Supply Will Not Be Affected
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech will pay Amgen $30 mil. to cancel Enbrel manufacturing agreement, transitioning capacity in its South San Francisco manufacturing facility to Avastin. Genentech is ramping up manufacturing at other facilities as well.